| Consolidated Statements of Operations Information |
Note 17. Consolidated Statements of Operations Information Revenue The Group’s revenue comprised: | | | | | | | | | | Years ended December 31: | | 2024 | | 2023 | | 2022 | Royalty, goods and products and services | | $ | 24,279 | | $ | 43,330 | | $ | 52,218 | Interest | | | 3,210 | | | 3,717 | | | 3,712 | Dividends | | | 166 | | | 146 | | | 268 | Other, including medical and real estate sectors | | | 7,647 | | | 7,751 | | | 7,491 | Revenue | | $ | 35,302 | | $ | 54,944 | | $ | 63,689 |
The revenue of $24,279 from royalty, goods and products and services for the year ended December 31, 2024 comprised royalty revenue of $20,046, energy of $4,171 and fees of $62. The revenue of $43,330 from royalty, goods and products and services for the year ended December 31, 2023 comprised royalty revenue of $35,234, energy of $6,931 and fees of $1,165. The revenue of $52,218 from royalty, goods and products and services for the year ended December 31, 2022 comprised royalty revenue of $28,970, energy of $21,555 and fees of $1,693. Costs and Expenses The Group’s costs of sales and services comprised: | | | | | | | | | | Years Ended December 31: | | 2024 | | 2023 | | 2022 | Royalty, goods and products and services | | $ | 8,532 | | $ | 12,689 | | $ | 23,677 | Write-down (Reversal of write-down) of inventories | | | 19 | | | (27) | | | (21) | Net fair value loss (gain) on investment property | | | (2,005) | | | 59 | | | (96) | Gain on dispositions of subsidiaries, net | | | (3,646) | | | — | | | (264) | Gains on settlements and derecognition of liabilities | | | — | | | (1,313) | | | (69) | Change in fair value of loan payable measured at FVTPL | | | (1,197) | | | 360 | | | 141 | Losses on securities, net | | | 218 | | | 2,794 | | | 2,436 | Other, including medical and real estate sectors | | | 5,142 | | | 4,512 | | | 4,078 | Total costs of sales and services | | $ | 7,063 | | $ | 19,074 | | $ | 29,882 |
Note 17. Consolidated Statements of Operations Information (continued) The Group’s net gain from dispositions of subsidiaries comprised: | | | | | | | | | | Years Ended December 31: | | 2024 | | 2023 | | 2022 | Net liabilities in excess of considerations received | | $ | (3,646) | | $ | — | | $ | (273) | Reclassification adjustment for the exchange differences upon dispositions of subsidiary | | | — | | | — | | | 9 | Gain on disposition of subsidiary, net (see Note 27) | | $ | (3,646) | | $ | — | | $ | (264) |
The Group included the following items in costs of sales and services: | | | | | | | | | | Years ended December 31: | | 2024 | | 2023 | | 2022 | Inventories as costs of goods sold (including depreciation expenses allocated to costs of goods sold) | | $ | 73 | | $ | 40 | | $ | 80 |
The Group’s selling, general and administrative expenses comprised: | | | | | | | | | | Years ended December 31: | | 2024 | | 2023 | | 2022 | Compensation (wages and salaries) | | $ | 6,293 | | $ | 5,418 | | $ | 4,443 | Legal and professional | | | 6,091 | | | 7,242 | | | 6,983 | Accounting | | | 1,765 | | | 1,646 | | | 885 | Consulting and fees | | | 3,693 | | | 3,095 | | | 6,529 | Depreciation and amortization | | | 858 | | | 932 | | | 784 | Office | | | 1,065 | | | 804 | | | 748 | Reimbursement of expenses (net of recovery) | | | 679 | | | 886 | | | 5,607 | Other | | | 4,891 | | | 4,159 | * | | 2,501 | | | $ | 25,335 | | $ | 24,182 | | $ | 28,480 |
* Including expenses of $542 relating to a planned acquisition which was terminated in 2023. Additional information on the nature of costs and expenses | | | | | | | | | | Years Ended December 31: | | 2024 | | 2023 | | 2022 | Depreciation, depletion and amortization | | $ | 7,221 | | $ | 7,929 | | $ | 10,699 | Employee benefits expenses* | | | 8,044 | | | 8,057 | | | 7,194 | Expenses for defined contribution plans and similar plans | | | — | | | 227 | | | 278 | Termination benefits | | | 1,424 | | | — | | | 394 |
* Employee benefits expenses do not include the directors’ fees of the Company. For directors’ fees, see Note 24.
|